Private company
Third Harmonic Bio, Inc.
American pharmaceutical preparations company, incorporated in Delaware. Summary from the record
Last updated Oct 19, 2026.
Overview
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Financial statements
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Research and development | $15.7M3 | $24.4M4 | $24.0M5 | $36.5M5 | ||
| Operating expenses | $19.0M3 | $37.7M4 | $44.0M5 | $58.9M5 | ||
| Operating income | -$19.0M3 | -$37.7M4 | -$44.0M5 | -$58.9M5 | ||
| Income before tax | -$29.6M3 | -$35.2M4 | -$30.8M5 | -$45.5M5 | ||
| Net income | -$29.6M3 | -$35.2M4 | -$30.8M5 | -$45.5M5 | ||
| Earnings per share | -$7.323 | $2.454 | $0.785 | $1.095 | ||
| Earnings per share (diluted) | -$7.323 | $2.454 | $0.785 | $1.095 | ||
| Shares (weighted, basic) | 4.0M shares3 | 14.4M shares4 | 39.6M shares5 | 41.7M shares5 | ||
| Shares (weighted, diluted) | 4.0M shares3 | 14.4M shares4 | 39.6M shares5 | 41.7M shares5 |
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Cash | $128.3M3 | $288.9M4 | $269.1M5 | $285.1M5 | ||
| Current assets | $129.2M3 | $292.8M4 | $272.4M5 | $290.5M5 | ||
| Property, plant and equipment | $03 | $35.0K4 | $169.0K5 | $130.0K5 | ||
| Total assets | $129.2M3 | $298.7M4 | $277.7M5 | $294.6M5 | ||
| Accounts payable | $1.8M3 | $2.1M4 | $1.8M5 | $1.9M5 | ||
| Current liabilities | $5.7M3 | $5.7M4 | $5.4M5 | $7.1M5 | ||
| Total liabilities | $5.7M3 | $9.6M4 | $8.6M5 | $9.5M5 | ||
| Retained earnings | -$48.2M3 | -$83.4M4 | -$114.2M5 | -$159.7M5 | ||
| Shareholders’ equity | -$18.4M3 | -$46.7M4 | $289.1M5 | $269.1M5 | $285.1M5 | |
| Shares outstanding | 4.2M shares3 | 39.4M shares4 | 40.1M shares5 | 44.9M shares5 | 45.1M shares5 |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Cash from operations | -$15.7M3 | -$34.9M4 | -$20.4M5 | -$34.5M5 | ||
| Stock-based compensation | $510.0K3 | $4.8M4 | $9.6M5 | $11.1M5 | ||
| Capital spending | $03 | $36.0K4 | $169.0K5 | $10.0K5 | ||
| Free cash flow | -$15.7M | -$35.0M | -$20.6M | -$34.5M | ||
| Cash from investing | $03 | -$36.0K4 | -$169.0K5 | -$10.0K5 | ||
| Cash from financing | $135.7M3 | $196.0M4 | $799.0K5 | $50.5M5 | ||
| Dividend per share | $0.003 | $0.004 | $0.004 | $0.005 |
Leadership
Who has led Third Harmonic Bio, Inc., and when. Pick a name to see everywhere that person has worked.
Chief executive
Chief financial officer
Chief operating officer
2025
- Chief executive officerNatalie C. Holles Sep 14, 2022 to now9
- Chief financial officerChristopher M. Murphy Jan 9, 2024 to now10
- Chief financial officerRobert Ho Sep 14, 2022 to Mar 8, 202311
- Chief operating officerJennifer Dittman Jan 17, 2025 to now12
Board members and other officers (14)
- Chief Scientific OfficerChristopher Dinsmore May 20, 2024 to now13
- Chief Development Oper OfficerJennifer Dittman May 20, 2024 to now14
- Chief Scientific OfficerAdrian S. Ray Sep 14, 2022 to Mar 8, 202315
- Chief Medical OfficerEdward R. Conner Sep 14, 2022 to now16
- Chief Administrative OfficerJulie Person Sep 14, 2022 to now17
- Board memberGeoff McDonough Mar 28, 2024 to now18
- Board memberDavid P. Bonita Sep 14, 2022 to now19
- Board memberHans Martin Seidel Sep 14, 2022 to now20
- Board memberMark T. Iwicki Sep 14, 2022 to now21
- Board memberMichael Gladstone Sep 14, 2022 to now22
- Board memberNatalie C. Holles Sep 14, 2022 to now9
- Board memberRobert J. Perez Sep 14, 2022 to Mar 8, 202323
- Board memberShao-Lee Lin Sep 14, 2022 to Oct 27, 202224
- Board memberThomas P. Soloway Sep 14, 2022 to now25
Timeline
- Sep 14, 2022New chief executive Natalie C. Holles becomes CEO9
Filings
220 filings to the SEC since October 2021: 3 annual reports, 8 quarterly reports, 29 major events, 97 insider forms, 30 large holders, 53 other. The latest 20:
- Nov 14, 2025SCHEDULE 13G/A EDGAR
- Aug 14, 20254 EDGAR
- Aug 14, 20254 EDGAR
- Aug 14, 20254 EDGAR
- Aug 14, 20254 EDGAR
- Aug 14, 20254 EDGAR
- Aug 14, 20254 EDGAR
- Aug 14, 20254 EDGAR
- Aug 11, 202515-12G EDGAR
- Jul 31, 2025EFFECT EDGAR
- Jul 31, 20258-K EDGAR
- Jul 31, 2025S-8 POS EDGAR
- Jul 31, 2025S-8 POS EDGAR
- Jul 31, 2025S-8 POS EDGAR
- Jul 31, 2025S-8 POS EDGAR
- Jul 31, 2025POS AM EDGAR
- Jul 31, 202525 EDGAR
- Jul 21, 20258-K EDGAR
- Jun 12, 20258-K EDGAR
- Jun 11, 20258-K EDGAR
The 220 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
19 open-market trades by officers, directors and large owners since October 2021: 4 buys and 15 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Nov 8, 2024 | Conner Edward R.Chief Medical Officer | Sale | 2,117 | $15.00 | $31.8K | Form 4 |
| Oct 29, 2024 | BVF INC/IL | Sale | 1,000,000 | $14.30 | $14.3M | Form 4 |
| Oct 28, 2024 | Conner Edward R.Chief Medical Officer | Sale | 2,673 | $15.00 | $40.1K | Form 4 |
| Sep 19, 2024 | Conner Edward R.Chief Medical Officer | Sale | 4,790 | $15.00 | $71.8K | Form 4 |
| Sep 19, 2024 | Person JulieCHIEF ADMINISTRATIVE OFFICER | Sale | 9,497 | $14.29 | $135.7K | Form 4 |
| Sep 18, 2024 | Person JulieCHIEF ADMINISTRATIVE OFFICER | Sale | 503 | $14.00 | $7.0K | Form 4 |
| Jun 26, 2024 | Person JulieCHIEF ADMINISTRATIVE OFFICER | Sale | 10,000 | $12.46 | $124.6K | Form 4 |
| Jun 7, 2024 | Dittman JenniferChief Operating Officer | Sale | 494 | $14.17 | $7.0K | Form 4 |
| May 20, 2024 | Dittman JenniferChief Operating Officer | Sale | 1,042 | $14.00 | $14.6K | Form 4 |
| May 16, 2024 | Dittman JenniferChief Operating Officer | Sale | 23,578 | $14.04 | $331.0K | Form 4 |
| May 9, 2024 | Holles Natalie C.CEO | Sale | 20,222 | $12.18 | $246.3K | Form 4 |
| Apr 11, 2024 | Holles Natalie C.CEO | Sale | 13,558 | $12.19 | $165.3K | Form 4 |
| Apr 4, 2024 | Person JulieCHIEF ADMINISTRATIVE OFFICER | Sale | 1,107 | $10.00 | $11.1K | Form 4 |
| Dec 5, 2023 | Person JulieCHIEF ADMINISTRATIVE OFFICER | Sale | 12,863 | $10.30 | $132.5K | Form 4 |
| Dec 5, 2023 | Conner Edward R.Chief Medical Officer | Sale | 4,790 | $10.03 | $48.0K | Form 4 |
| Dec 20, 2022 | BIOTECHNOLOGY VALUE FUND II LP | Buy | 214,063 | $4.11 | $879.8K | Form 4 |
| Sep 19, 2022 | OrbiMed Capital GP VII LLCDirector | Buy | 300,000 | $17.00 | $5.1M | Form 4 |
| Sep 19, 2022 | Bonita David PDirector | Buy | 300,000 | $17.00 | $5.1M | Form 4 |
| Sep 19, 2022 | Atlas Venture Associates XI, LLC10% owner | Buy | 300,000 | $17.00 | $5.1M | Form 4 |
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- Nantahala Capital Management, LLCSCHEDULE 13G/A, 2 filings May 15, 2025 to Nov 14, 202526
- EcoR1 Capital, LLCSCHEDULE 13G/A, 3 filings Sep 13, 2023 to May 15, 202527
- FMR LLCSCHEDULE 13G/A, 2 filings Feb 12, 2025 to May 12, 202528
- BIOTECHNOLOGY VALUE FUND L PSCHEDULE 13G/A, 4 filings Sep 26, 2022 to Apr 16, 202529
- BML Investment Partners, L.P.SCHEDULE 13G, 1 filing Feb 14, 202530
- GENERAL ATLANTIC, L.P.SCHEDULE 13D/A, 3 filings Sep 28, 2022 to Feb 13, 202531
- RA CAPITAL MANAGEMENT, L.P.SC 13G/A, 4 filings Sep 26, 2022 to Nov 14, 202432
- T. Rowe Price Investment Management, Inc.SC 13G, 1 filing Nov 14, 202433
- ORBIMED ADVISORS LLCSC 13D/A, 2 filings Sep 28, 2022 to Nov 12, 202434
- Atlas Venture Fund XI, L.P.SC 13D/A, 2 filings Sep 29, 2022 to Nov 5, 202435
- TCG Crossover GP II, LLCSC 13G, 1 filing Sep 27, 202436
- Stonepine Capital Management, LLCSC 13G/A, 2 filings Jan 19, 2023 to Feb 13, 202437
- Bain Capital Life Sciences Investors, LLCSC 13G/A, 2 filings Sep 29, 2022 to Feb 14, 202338
- Novartis Institutes for BioMedical Research, Inc.SC 13G, 1 filing Feb 8, 202339
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11SEC EDGARRobert Ho, Chief financial officer
- 12
- 13
- 14
- 15
- 16
- 17
- 18SEC EDGARGeoff McDonough, Board member
- 19SEC EDGARDavid P. Bonita, Board member
- 20SEC EDGARHans Martin Seidel, Board member
- 21SEC EDGARMark T. Iwicki, Board member
- 22SEC EDGARMichael Gladstone, Board member
- 23SEC EDGARRobert J. Perez, Board member
- 24SEC EDGARShao-Lee Lin, Board member
- 25SEC EDGARThomas P. Soloway, Board member
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39